Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million ...

Robert F. Kennedy Jr. announced the Department of Health and Human Services (HHS) plans to cancel contracts and pull funding ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Pfizer's weekly Canadian shipment of 2.4 million doses was temporarily delayed this week, causing provinces to change appointments to Moderna due to an increase in supply of that shot and to avoid ...

In clinical trials, Moderna showed 94.1 per cent efficacy in preventing COVID-19 two weeks after a second dose, comparable to Pfizer’s 95 per cent.

Pfizer is the only vaccine currently approved for people aged 12 to 17. "Any youths who are affected by the delay will be contacted directly to discuss arrangements for immunization," the SHA said.